Levetiracetam Compared with Valproic Acid for the Prevention of Postoperative Seizures After Supratentorial Tumor Surgery: A Retrospective Chart Review
Tóm tắt
Antiepileptic drugs are commonly given for perioperative prophylaxis after brain tumor surgery, and there has been growing interest in levetiracetam, a second-generation antiepileptic drug. This retrospective study compared the seizure outcomes, side effects and durability of levetiracetam with valproic acid after a craniotomy for supratentorial brain tumors. Between 2009 and 2012, 282 consecutive patients with a supratentorial brain tumor underwent a craniotomy at Seoul National University Bundang Hospital. Of these patients, 51 (18.1 %) and 231 (81.9 %) were pre-operatively administered levetiracetam and valproic acid, respectively. The postoperative seizure outcomes (within 1 month after surgery) and the long-term side effects of both drugs were evaluated. Of the 51 patients in the levetiracetam group, 4 (7.8 %) experienced postoperative seizures after brain tumor surgery, and 15 (6.5 %) of the 231 patients in the valproic acid group experienced postoperative seizures (p = 0.728). The long-term complication rate of the valproic acid group (26.8 %; 62/231) was significantly higher than that of the levetiracetam group (9.8 %; 5/51) [p = 0.010]. In the valproic acid group, 10 hepatotoxicities, 20 hyperammonemias and 10 hematologic abnormalities (6 thrombocytopenias, 3 pancytopenias, and 1 leucopenia) occurred. Moreover, 89 patients (38.5 %) in the valproic acid group changed or added other anticonvulsants because of side effects or uncontrolled seizures, whereas only 9 patients (17.6 %) in the levetiracetam group changed or added other anticonvulsants (p = 0.005). The postoperative seizure control rates of levetiracetam and valproic acid were not statistically significantly different; however, levetiracetam may be superior to valproic acid in terms of its safety and durability after supratentorial tumor surgery.
Tài liệu tham khảo
Tremont-Lukats IW, Ratilal BO, Armstrong T, Gilbert MR. Antiepileptic drugs for preventing seizures in people with brain tumors. Cochrane Database Syst Rev. 2008(2):CD004424. doi:10.1002/14651858.CD004424.pub2.
Boarini DJ, Beck DW, VanGilder JC. Postoperative prophylactic anticonvulsant therapy in cerebral gliomas. Neurosurgery. 1985;16(3):290–2.
O’Laoire SA. Epilepsy following neurosurgical intervention. Acta neurochirurgica Supplementum. 1990;50:52–4.
Klimek M, Dammers R. Antiepileptic drug therapy in the perioperative course of neurosurgical patients. Curr Opin Anaesthesiol. 2010;23(5):564–7. doi:10.1097/ACO.0b013e32833e14f2.
Batchelor TT, Byrne TN. Supportive care of brain tumor patients. Hematol Oncol Clin North Am. 2006;20(6):1337–61. doi:10.1016/j.hoc.2006.09.013.
Glantz MJ, Cole BF, Forsyth PA, Recht LD, Wen PY, Chamberlain MC, et al. Practice parameter: anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2000;54(10):1886–93.
Oberndorfer S, Piribauer M, Marosi C, Lahrmann H, Hitzenberger P, Grisold W. P450 enzyme inducing and non-enzyme inducing antiepileptics in glioblastoma patients treated with standard chemotherapy. J Neuro-Oncol. 2005;72(3):255–60. doi:10.1007/s11060-004-2338-2.
Merrell RT, Anderson SK, Meyer FB, Lachance DH. Seizures in patients with glioma treated with phenytoin and levetiracetam. J Neurosurg. 2010;113(6):1176–81. doi:10.3171/2010.5.JNS091367.
van Breemen MS, Wilms EB, Vecht CJ. Epilepsy in patients with brain tumours: epidemiology, mechanisms, and management. Lancet Neurol. 2007;6(5):421–30. doi:10.1016/S1474-4422(07)70103-5.
Otoul C, De Smedt H, Stockis A. Lack of pharmacokinetic interaction of levetiracetam on carbamazepine, valproic acid, topiramate, and lamotrigine in children with epilepsy. Epilepsia. 2007;48(11):2111–5. doi:10.1111/j.1528-1167.2007.01201.x.
Bauer J, Ben-Menachem E, Kramer G, Fryze W, Da Silva S, Kasteleijn-Nolst Trenite DG. Levetiracetam: a long-term follow-up study of efficacy and safety. Acta Neurologica Scandinavica. 2006;114(3):169–76. doi:10.1111/j.1600-0404.2006.00657.x.
Krakow K, Walker M, Otoul C, Sander JW. Long-term continuation of levetiracetam in patients with refractory epilepsy. Neurology. 2001;56(12):1772–4.
Mink S, Muroi C, Seule M, Bjeljac M, Keller E. Levetiracetam compared to valproic acid: plasma concentration levels, adverse effects and interactions in aneurysmal subarachnoid hemorrhage. Clin Neurol Neurosurg. 2011;113(8):644–8. doi:10.1016/j.clineuro.2011.05.007.
Herman ST. Epilepsy after brain insult: targeting epileptogenesis. Neurology. 2002;59(9 Suppl 5):S21–6.
Olafsson E, Ludvigsson P, Gudmundsson G, Hesdorffer D, Kjartansson O, Hauser WA. Incidence of unprovoked seizures and epilepsy in Iceland and assessment of the epilepsy syndrome classification: a prospective study. Lancet Neurol. 2005;4(10):627–34. doi:10.1016/S1474-4422(05)70172-1.
Zachenhofer I, Donat M, Oberndorfer S, Roessler K. Perioperative levetiracetam for prevention of seizures in supratentorial brain tumor surgery. J Neuro-Oncol. 2011;101(1):101–6. doi:10.1007/s11060-010-0235-4.
Foy PM, Chadwick DW, Rajgopalan N, Johnson AL, Shaw MD. Do prophylactic anticonvulsant drugs alter the pattern of seizures after craniotomy? J Neurol Neurosurg Psychiatry. 1992;55(9):753–7.
Soroker N, Groswasser Z, Costeff H. Practice of prophylactic anticonvulsant treatment in head injury. Brain Injury [BI]. 1989;3(2):137–40.
Temkin NR. Antiepileptogenesis and seizure prevention trials with antiepileptic drugs: meta-analysis of controlled trials. Epilepsia. 2001;42(4):515–24.
Mauro AM, Bomprezzi C, Morresi S, Provinciali L, Formica F, Iacoangeli M, et al. Prevention of early postoperative seizures in patients with primary brain tumors: preliminary experience with oxcarbazepine. J Neuro-Oncol. 2007;81(3):279–85. doi:10.1007/s11060-006-9229-7.
Browne TR, Szabo GK, Leppik IE, Josephs E, Paz J, Baltes E, et al. Absence of pharmacokinetic drug interaction of levetiracetam with phenytoin in patients with epilepsy determined by new technique. J Clin Pharmacol. 2000;40(6):590–5.
Pursche S, Schleyer E, von Bonin M, Ehninger G, Said SM, Prondzinsky R, et al. Influence of enzyme-inducing antiepileptic drugs on trough level of imatinib in glioblastoma patients. Curr Clin Pharmacol. 2008;3(3):198–203.
Baltes S, Gastens AM, Fedrowitz M, Potschka H, Kaever V, Loscher W. Differences in the transport of the antiepileptic drugs phenytoin, levetiracetam and carbamazepine by human and mouse P-glycoprotein. Neuropharmacology. 2007;52(2):333–46. doi:10.1016/j.neuropharm.2006.07.038.
Marson AG, Williamson PR, Clough H, Hutton JL, Chadwick DW. Carbamazepine versus valproate monotherapy for epilepsy: a meta-analysis. Epilepsia. 2002;43(5):505–13.
Eyal S, Yagen B, Sobol E, Altschuler Y, Shmuel M, Bialer M. The activity of antiepileptic drugs as histone deacetylase inhibitors. Epilepsia. 2004;45(7):737–44. doi:10.1111/j.0013-9580.2004.00104.x.
Li XN, Shu Q, Su JM, Perlaky L, Blaney SM, Lau CC. Valproic acid induces growth arrest, apoptosis, and senescence in medulloblastomas by increasing histone hyperacetylation and regulating expression of p21Cip1, CDK4, and CMYC. Mol Cancer Ther. 2005;4(12):1912–22. doi:10.1158/1535-7163.MCT-05-0184.
Weller M, Gorlia T, Cairncross JG, van den Bent MJ, Mason W, Belanger K, et al. Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma. Neurology. 2011;77(12):1156–64. doi:10.1212/WNL.0b013e31822f02e1.
Itoh H, Suzuki Y, Fujisaki K, Sato Y, Takeyama M. Correlation between plasma ammonia level and serum trough concentration of free valproic acid in patients with epilepsy. Biol Pharm Bull. 2012;35(6):971–4.
Schmid MM, Freudenmann RW, Keller F, Connemann BJ, Hiemke C, Gahr M, et al. Non-fatal and fatal liver failure associated with valproic acid. Pharmacopsychiatry. 2012;46(2):63–8. doi:10.1055/s-0032-1323671.
Maschio M, Dinapoli L, Sperati F, Pace A, Fabi A, Vidiri A, et al. Levetiracetam monotherapy in patients with brain tumor-related epilepsy: seizure control, safety, and quality of life. J Neuro-Oncol. 2011;104(1):205–14. doi:10.1007/s11060-010-0460-x.
Rosati A, Buttolo L, Stefini R, Todeschini A, Cenzato M, Padovani A. Efficacy and safety of levetiracetam in patients with glioma: a clinical prospective study. Arch Neurol. 2010;67(3):343–6. doi:10.1001/archneurol.2009.335.
Newton HB, Dalton J, Goldlust S, Pearl D. Retrospective analysis of the efficacy and tolerability of levetiracetam in patients with metastatic brain tumors. J Neuro-Oncol. 2007;84(3):293–6. doi:10.1007/s11060-007-9373-8.
Milligan TA, Hurwitz S, Bromfield EB. Efficacy and tolerability of levetiracetam versus phenytoin after supratentorial neurosurgery. Neurology. 2008;71(9):665–9. doi:10.1212/01.wnl.0000324624.52935.46.
Szaflarski JP, Sangha KS, Lindsell CJ, Shutter LA. Prospective, randomized, single-blinded comparative trial of intravenous levetiracetam versus phenytoin for seizure prophylaxis. Neurocrit Care. 2010;12(2):165–72. doi:10.1007/s12028-009-9304-y.
Kern K, Schebesch KM, Schlaier J, Hansen E, Feigl GC, Brawanski AT, et al. Levetiracetam compared to phenytoin for the prevention of postoperative seizures after craniotomy for intracranial tumours in patients without epilepsy. J Clin Neurosci Off J Neurosurg Soc Aust. 2012;19(1):99–100. doi:10.1016/j.jocn.2011.07.021.
Zafar SN, Khan AA, Ghauri AA, Shamim MS. Phenytoin versus leviteracetam for seizure prophylaxis after brain injury—a meta analysis. BMC Neurol. 2012;12:30. doi:10.1186/1471-2377-12-30.
Sethi NK, Milligan TA, Hurwitz S, Bromfield EB. Efficacy and tolerability of levetiracetam versus phenytoin after supratentorial neurosurgery. Neurology. 2009;73(2):159 (author reply). doi:10.1212/01.wnl.0000349664.64710.86.
Lim DA, Tarapore P, Chang E, Burt M, Chakalian L, Barbaro N, et al. Safety and feasibility of switching from phenytoin to levetiracetam monotherapy for glioma-related seizure control following craniotomy: a randomized phase II pilot study. J Neuro-Oncol. 2009;93(3):349–54. doi:10.1007/s11060-008-9781-4.